Clinical Trials Using Fluciclovine F18

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fluciclovine F18. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-13 of 13
  • Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET / CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma

    This phase II trial studies how well a positron emission tomography (PET) / computed tomography (CT) scan using fluciclovine F18 compared with a PET / CT scan with gallium Ga 68-labeled PSMA-11 works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and gallium Ga 68-labeled PSMA-11 are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET / CT scan. It is not yet known whether giving fluciclovine F18 or gallium Ga 68-labeled PSMA-11 may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
    Location: 4 locations

  • An Investigational Scan (Fluciclovine F18 PET) for the Diagnosis of Cervical or Endometrial Cancer

    This phase IV trial studies how well an investigational scan called fluciclovine F18 positron emission tomography (PET) works in diagnosing cervical or endometrial cancer. Fluciclovine F18 is a type of radioactive diagnostic agent that is injected into the patient and then taken up by tumor cells, which can then be visualized by using PET imaging scans. The purpose of this study is to determine the diagnostic potential of fluciclovine F18 PET when compared to standard of care imaging scans.
    Location: 5 locations

  • Clinical Utility of 18F-Fluciclovine PET / MRI Imaging following Focal Cryo-Ablation of Prostate Cancer

    This trial studies 18F-fluciclovine positron emission tomography (PET) / magnetic resonance imaging (MRI) in identifying the recurrence of prostate cancer in men who have undergone focal cryoablation. PET imaging uses a radioactive drug (tracer) to make images of tissues in the body and how they are functioning. The PET tracer used in this study, 18F-fluciclovine, binds or sticks more to prostate cancer cells than surrounding normal tissues, which can be seen on the images. MRI uses radio waves and a magnet to make pictures of areas inside the body. The purpose of this study is to see if PET imaging with 18F-fluciclovine helps to identify recurrence of prostate cancer.
    Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

  • 18F-Fluciclovine, PET / CT and MRI, and cfDNA in Differentiating Tumor Progression in Patients with Glioblastoma

    This phase I trial studies how well 18F-fluciclovine positron emission tomography (PET) / computed tomography (CT) and magnetic resonance imaging (MRI) scans and circulating cell-free deoxyribonucleic acid (cfDNA) work in differentiating tumor progression in patients with glioblastoma. 18F-fluciclovine is a radioactive tracer used to image areas where doctors think the tumor has come back or if there is a change in the area because of previous treatment. PET / CT and MRI scans are types of imaging that can track where 18F-fluciclovine is taken up in the body. cfDNA is a type of substance that is shed by a tumor into the bloodstream and may provide useful information about the tumor. Giving 18F-fluciclovine PET / CT and MRI scans and studying cfDNA may help doctors better understand tumor growth and disease progression in patients with glioblastoma.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • 18F-Fluciclovine PET / CT to Distinguish Tumor Progression From Radiation Necrosis

    This phase IV trial studies how well 18F-fluciclovine positron emission tomography (PET) / computed tomography (CT) works in diagnosing radiation necrosis versus tumor progression in patients with cancer that has spread to the brain (metastatic) following stereotactic radiosurgery. Radiation necrosis is damage that occurs to normal brain tissue caused by radiation and looks similar to a tumor that is growing, spreading, or getting worse (tumor progression) when viewed using magnetic resonance imaging (MRI). 18F-fluciclovine PET / CT may be able to distinguish radiation necrosis from tumor progression in cases where the MRI is inconclusive.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • F18 Fluciclovine PET / CT in Assessing Tumor Volume and Radiation Therapy Response in Patients with Glioblastoma Undergoing Surgery

    This early phase I trial studies how well F18 fluciclovine positron emission tomography (PET) / computed tomography (CT) works in assessing tumor volume and radiation therapy response in patients with glioblastoma undergoing surgery. Radioactive imaging agents, such as F18 fluciclovine, used during PET / CT scan may help measure tumor size compared to standard of care magnetic resonance imaging (MRI) contrast agents in patients receiving radiation therapy.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Fluciclovine F18 PET / CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients with Metastatic Cervical Nodal Disease

    This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET) / computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has spread to the cervical lymph nodes. Fluciclovine F18 during a PET / CT scan may work better in helping doctors learn where the cancer started (called the site of origin) and directing treatment planning compared to standard fludeoxyglucose F-18 (FDG) PET-CT scans.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Fluciclovine F18 PET / CT Imaging in Assessing Hormone-Naive Men with Prostate Cancer that has Spread to the Bone

    This phase II trial studies how well fluciclovine 18F PET / CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth. PET / CT uses x-rays to take pictures inside the body. Comparing results of fluciclovine 18F PET / CT imaging may help doctors predict a patient's response to treatment and help plan the best treatment.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • 18-F Fluciclovine PET / MRI in Diagnosing Prostate Cancer in Patients with Suspicious Lesions

    This trial studies how well 18-F fluciclovine positron emission tomography (PET) / magnetic resonance imaging (MRI) works in diagnosing prostate cancer in patients with suspicious lesions. 18-F fluciclovine is taken up to a greater extent in prostate cancer cells than in surrounding normal tissues, and may be more accurate in diagnosing prostate cancer when given for PET / MRI.
    Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

  • Fluciclovine F18 PET / CT in Diagnosing Bone Metastases in Patients with Metastatic Castration-Resistant or Biochemically Recurrent Prostate Cancer

    This phase IV trial studies how well fluciclovine F18 positron emission tomography (PET) / computed tomography (CT) works in diagnosing cancer that has spread to the bone in patients with prostate cancer that is castration-resistant and has spread to other places in the body or has increasing prostate-specific antigen (PSA) following treatment. Fluciclovine F18 is a type of imaging agent, that when injected into the bloodstream, is taken up by prostate cancer cells. Using a PET / CT scan, doctors may be able to see the fluciclovine F18 and thus the cancer cells that have spread to the bone.
    Location: Banner University Medical Center - Tucson, Tucson, Arizona

  • Fluorine F18 Fluciclovine and Fluorine F 18 Fluorothymidine PET / CT in Diagnosing Patients with High-Grade Brain Tumors

    This phase II trial studies how well fluorine f18 fluciclovine and fluorine f18 fluorothymidine PET / CT work in diagnosing patients with high-grade brain tumors. Diagnostic procedures, such as f18 fluciclovine and fluorine f18 fluorothymidine positron-emission tomography (PET) / computed tomography (CT), may help find and diagnose high-grade brain tumors and find out how far the disease has spread.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Fluciclovine (18F) PET / CT Imaging in Indicating Early Metastatic Disease in Patients with High or Unfavorable Intermediate-Risk Prostate Cancer

    This clinical trial studies how well fluciclovine (18F) positron emission tomography (PET) / computed tomography (CT) imaging works in indicating early metastatic disease in patients with high or unfavorable intermediate-risk prostate cancer. Radioactive tracers, such as 18F may enter prostate tumor cells. PET / CT imaging performed with 18F may be a better way to determine if cancer has spread outside of the prostate.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Fluciclovine (18F) PET / CT in Predicting Treatment Response in Patients with Recurrent or Metastatic Castration-Resistant Prostate Cancer Receiving Chemotherapy

    This phase II trial studies the use of fluciclovine (18 fluorine [F]) positron emission tomography (PET) / computed tomography (CT) in predicting treatment response in patients with castration-resistant prostate cancer that has come back or spread to other places in the body and are receiving chemotherapy. Fluciclovine (18F) is a radiotracer that accumulates in tumor cells and may be useful in imaging tumors using PET scans. PET / CT scans make detailed, computerized pictures of areas inside the body where fluciclovine (18F) accumulates. Diagnostic procedures, such as fluciclovine (18F) PET / CT, may help doctors predict treatment response in patients receiving chemotherapy.
    Location: 2 locations